Originally developed in the 1990s, as a fat burning (lipolytic) compound, AOD9604 stimulates the breakdown or destruction of fat cells (lipolysis) and inhibits the metabolic formation of fat (lipogenesis) in animal studies
Some compounding pharmacies and licensed providers offer it under specific conditions and through physician oversight
Monthly PRP or growth factor treatments
Summary Keywords antioxidant, bronchiectasis, COPD, cystic fibrosis, mucolytic, N-acetylcysteine Citation Barne M, Shevade M, Bhattacharyya P, Christopher DJ, Nair S, Abhyankar N, Halder I, Vora A, Khanna A, Swarnakar R, Chhajed P, Santhalingam B, Nair A and Salvi S (2026) N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR)
Co-developed with a pharmaceutical company for a real skincare solution
[DOI] [PMC free article] [PubMed] [Google Scholar] 118.Pouny Y, Rapaport D, Mor A, Nicolas P, Shai Y